Valneva And Pfizer Release Phase 2 Booster Findings For Lyme Disease Vaccine Candidate In Pediatric And Adolescent Populations
Portfolio Pulse from Benzinga Newsdesk
Valneva and Pfizer have released Phase 2 booster findings for their Lyme disease vaccine candidate in pediatric and adolescent populations. The results show promising efficacy and safety profiles.
September 07, 2023 | 6:39 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Pfizer's partnership with Valneva on the Lyme disease vaccine could potentially boost its product portfolio and revenues if the vaccine receives approval.
The positive Phase 2 results for the Lyme disease vaccine could potentially lead to a new revenue stream for Pfizer if the vaccine gets approved. This could positively impact Pfizer's stock in the short term.
CONFIDENCE 80
IMPORTANCE 70
RELEVANCE 50
POSITIVE IMPACT
Valneva's partnership with Pfizer on the Lyme disease vaccine could potentially boost its product portfolio and revenues if the vaccine receives approval.
The positive Phase 2 results for the Lyme disease vaccine could potentially lead to a new revenue stream for Valneva if the vaccine gets approved. This could positively impact Valneva's stock in the short term.
CONFIDENCE 80
IMPORTANCE 70
RELEVANCE 50